Alzamend Neuro Inc Ordinary Shares ALZN 深 滬
等待開盤 12-17 09:30:00 美东时间
2.16
+0.050
+2.37%
華盛通- 最 高2.1828
- 今 開2.10
- 成交量 2.04万股
- 最 低 2.10
- 昨 收 2.11
- 總市值 678.22万
- 52周最高 11.70
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 1.88
- 委 比 -96.47%
- 總股本 313.99万
- 歷史最高 45292.50
- 量 比 0.42
- 振 幅 3.92%
- 歷史最低 2.10
- 每 手 1
- 風險率 3.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alzamend Neuro Q2 EPS $(0.30) Beats $(1.96) Estimate
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(1.96) by 84.65 percent. This is a 91.69 percent increase over losses of $(3.61) per share from
12-10 06:37
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.
11-19 20:30
Alzamend Neuro Issues New Common Stock Shares
Alzamend Neuro ( ($ALZN) ) has provided an announcement. Between October 1 and ...
10-10 05:03
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Alzamend Neuro Boosts Liquidity with Stock Issuance
Alzamend Neuro ( ($ALZN) ) has provided an update. Between September 17 and Sep...
09-26 05:01
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $45 to $42.
09-25 20:02
Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.69) by 85.51 percent. This is a 88.79 percent increase over losses of $(11.42) per share from
09-11 04:41
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $180 to $45.
08-21 17:32
Alzamend Neuro Increases Common Stock Through Conversion
Alzamend Neuro ( ($ALZN) ) has issued an announcement. Between July 23, 2025, a...
08-02 05:06
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro, Inc. will present a study at MHSRS 2025 comparing lithium brain-to-plasma exposure in PTSD patients using AL001 and lithium carbonate. AL001 is a novel lithium-delivery system designed to improve brain targeting and reduce systemic side effects. The study aims to establish optimal dosing for PTSD and other conditions. Alzamend is advancing clinical trials for AL001 to treat Alzheimer's, bipolar disorder, major depressive disorder,...
07-28 12:00
